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the implication of the Epac—induced small G proteins and theirs 
networks.
In cardiomyocyte primary culture, we show that Epac activates the 
small G protein Ras, Rac and Rap. The Epac-induced hypertrophic 
effect is mediated by Ras and Rac activation. This Epac-induced 
activation of Ras is not in uenced by Rac or Rap and is due to 
a Ca2+ release in response to phospholipase C and IP3 receptor 
activation. Moreover, we show that Ras mediates the Epac-induced 
activation of the pro-hypertrophic CaMKII/MEF2 and calcineurin/
NFAT signalling pathways which are both necessary for hypertrophy. 
Epac has been initially identi ed as a GEF for the small G proteins 
Rap. Surprisingly, the Epac hypertrophic effect is independent 
of its classical effector Rap. The Epac-induced Rap1 signalling 
cascade involves PKCε translocation, which is a key actor of 
multiple cellular phosphorylations. This  nding is in agreement 
with other Rap functions reported in the literature such as cell to 
cell communication and adhesion.
Altogether, these data present new insights into the Epac signaling 
network with both pro-hypertrophic and non-hypertrophic effects.
- Morel E, Marcantoni A, Gastineau M, Birkedal R, Rochais F, 
Garnier A, Lompré AM, Vandecasteele G, Lezoualc’h F. cAMP-
binding protein Epac induces cardiomyocyte hypertrophy. Circ Res. 
97 : 1296-304, 2005
- Métrich M, Lucas A, Gastineau M, Samuel JL, Heymes C, Morel 
E, Lezoualc’h F.
Epac mediates beta-adrenergic receptor-induced cardiomyocyte 
hypertrophy. Circ Res. 102 : 959-65, 2008
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IS PRIMARY ALDOSTERONISM A CHANNELOPATHY ?
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2 Département de Génétique, Hôpital Européen Georges 
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In mouse models the genetic deletion of TWIK-related acid-sensitive 
K (TASK)-1 and TASK-3 channels removes an important background 
K current that results in a marked depolarization of adrenal zona 
glomerulosa cell membrane potential, leading to the autonomous 
overproduction of aldosterone. The importance of TASK channel 
dysfunction in human primary aldosteronism (PAL) however, is 
uncertain, motivating their molecular analysis. We screened coding 
exons and  anking intronic sequences of KCNK3 and KCNK9 (genes 
coding for TASK 1 and TASK 3 respectively) in 825 PAL patients for 
germline DNA sequence variants. A total of 14 different coding 
sequence variants were found in 19 patients. The variants include 8 
different synonymous mutations and 6 different missense variants. 
In silico predictions (PolyPhen, SIFT and Alamut) suggested the 
non-synonymous mutations to be potentially damaging. Analysis 
of mutated channel function by heterologous expression, however, 
revealed the missense mutations detected were non-functional. 
As somatic mutations may be involved in some cases of sporadic 
PAL, sequencing 90 patients for tumoral DNA sequence variants is 
underway. We are also investigating expression of TASK 1 and TASK 
3 by in-situ hybridization and immunohistochemistry on adrenal 
tissue sections of 150 PAL patients who have undergone surgery.
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ENDOTHELIAL ESTROGEN RECEPTOR ALPHA 
MEDIATES THE ATHEROPROTECTIVE ACTION 
OF ESTRADIOL IN LDLR DEFICIENT MICE
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Background — Although estrogen administration to hysterectomized 
menopausal women did not prevent the occurence of myocardial 
infarction in a randomized controlled trial (WHI 2004), 
epidemiological studies suggest and experimental results clearly 
demonstrate a major atheroprotective action of estrogens. The 
goal of the present study was to identify the cellular target(s) 
accounting for the estradiol (E2) bene cial action on fatty streak 
development.
Methods and Results — We  rst con rmed the key role of estrogen 
receptor α (ERα) in atheroprotective effect of E2 as this action 
was completely abolished in mice de cient both in Low Density 
Lipoprotein receptor (LDLr) and in ERα. Comparison of LDLr-
/- mice transplanted with either ERα+/+ or ERα-/- bone marrow 
showed that functional ERα in the hematopoietic lineage is not 
required for E2 atheroprotection. We then showed that ERα  oxed 
mice (ERα ox/ ox) bred with the Tie2-Cre mice on the LDLr-
/- background had a complete inactivation of ERα both in bone 
marrow and in endothelial cells. Remarkably, in this mouse model, 
the E2 atheroprotective action was completely abolished.
Conclusions — Altogether, this is the  rst in vivo demonstration that 
endothelial ERα represents a key target of the atheroprotective 
effect of E2, whereas the hematopoietic ERα is dispensable for 
the protective action. Selective estrogen receptor modulators that 
mimic this endothelial action of E2 should now be considered in 
hormonal treatment as well as in atheroprotection.
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MODELISATION PHYSIOLOGIQUE INTEGRATIVE 
DE LA REGULATION DE LA PRESSION ARTERIELLE 
ET DU SYSTEME RENINE-ANGIOTENSINE CIRCULANT
F. GUILLAUD 1, P. HANNAERT 1
1 Inserm U927 — CHU La Milétrie, Poitiers, France
Introduction — Le SRA est impliqué dans l’homéostasie hydrosodée 
et la régulation de la pression artérielle (PA). L’objectif du projet 
Saphir (Thomas et al., Phil Trans R Soc A, 2008) est le développement 
d’un modèle multiniveaux du système cardiovasculaire rénal (CVR). 
Nous présentons ici la modélisation du SRA circulant, intégré au 
modèle circulatoire de Guyton.
Modelisation — Le modèle est implémenté sous Simulink© 
(Mathworks). Hypothèses : (i) la rénine est produite par l’appareil 
juxtaglomérulaire (JGA) et l’artériole afférente ; (ii) la production 
de rénine est inhibée par la pression de perfusion, le signal TGF 
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(tubuloglomerular feedback), et l’angiotensine II (AII), (iii) elle est 
accrue par l’activité sympathique rénale.
Resultats — Après 7 J de régime hypo, normo et hypersodé (48, 144 
et 432 mmol/j) : PAM = 96, 100 et 110 mmHg ; PRA = 18, 16 et 13 pM/
min. Sous régime hyposodé, l’inhibition de EC (δPAM~8 mmHg) réduit 
AII (2 pM) et accroît PRA et rénine (x30). L’inhibition de la rénine 
(δPAM~5 mmHg) réduit Ang II (2 pM) et augmente la rénine du même 
facteur. Comparaison à un jeu de données cliniques : Nussberger 
et al., 2001, volontaires sains, apport normosodé, inhibition 
de la rénine (90 %, avec Aliskiren©). Les 3 premières heures sont 
reproduites : écart moyen 0,3 pM/min et 2,3 pM, pour PRA et rénine 
resp. (n  = 3) ; entre 4 et 24 h, le modèle dévie (rms = 7 pM/min et 5 
pM, n = 3), tout en restant semi-quantitatif. Nous avons simulé deux 
types d’hypertension : (i) masse rénale réduite (2/3) et apport sodé 
(500 mmol/j), (ii) hyperaldostéronisme primaire (aldo x10). Dans les 
deux cas : PAM augmente de ~40 mmHg en ~8j ; PRA diminue à ~6 
pM/min ; la simulation d’un diurétique (natriurèse x3) réduit PAM 
de ~20 mmHg en ~4 j (PRA partiellement normalisée, de 20 et 50 %, 
resp.).
Conclusion — Notre modèle manifeste un comportement réaliste 
(temps et amplitudes) en réponse aux manœuvres de contrôle de la 
PA. L’ajustement quantitatif des paramètres du modèle, la mise-à-
jour continue des modules, et son encadrement par des pathologies 
dé nies (hypertensions primaires,…) permettra de simuler des 
patients hypertendus et les variabilités associées (polymorphismes 
génétiques, réponse thérapeutique,…).
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Overactivity of the brain renin-angiotensin system (RAS) has 
been involved in the development of hypertension (HTA) in 
several animal models, such as DOCA-salt rats, a hypertension 
salt-dependent model. We previously reported that in the murine 
brain, AngII is converted to AngIII by aminopeptidase A (APA). We 
also showed that AngIII is one of the main effector peptides of 
the central RAS in the control of blood pressure (BP). Therefore 
the inhibition of brain APA, but not peripheral APA, with EC33, 
a speci c and selective APA inhibitor normalizes BP. Thus APA 
represents a potential candidate target for the treatment of 
HTA. If APA inhibitors are to be used as central antihypertensive 
agents, they must be able, after oral administration, to block 
brain APA activity. This was achieved with RB150, an orally active 
prodrug obtained by dimerization of EC33 through a disul de 
bond. Thus, RB150 po administered in conscious DOCA-salt rats, 
crossed intestinal, hepatic and blood-brain barriers and inhibited 
brain APA activity until a value similar to that measured in the 
brain of normotensive rats. This resulted in DOCA-salt rats but 
not in normotensive rats in a marked dose-dependent reduction 
in BP (ED50: 0,5 mg/kg) in less than two hours for up to several 
hours, without changing heart rate. In addition, this treatment 
decreases plasma vasopressin levels inducing increased diuresis, 
which by limiting the  uid compartment, contributes to decrease 
BP. Thus, RB150 could constitute the prototype of a new class of 
central antihypertensive agents.
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Objectives — Drug-eluting stents releasing antimitotic drugs are 
frequently used in patients undergoing percutaneous coronary 
interventions. Although these stents inhibit proliferation of vascular 
smooth muscle cells and thus reduce rates of early stenosis, they 
also impair proliferation of endothelial cells. The resulting delayed 
arterial healing increases the risk of thrombosis and leads to higher 
late stent restenosis. Optimization of endothelium repair is then 
necessary to prevent intimal thickening and in-stent restenosis.
Methods — Using a mouse model of carotid injury, we previously 
demonstrated that 17βestradiol (E2) accelerates endothelium 
regeneration through estrogen receptor ERα but not ERβ (1) and 
involvement of FGF-2 (2). However, the molecular and cellular 
mechanisms underlying this bene cial effect still remain poorly 
understood, mainly due to the lack of appropriate models and tools 
to visualize endothelium. Here, we employed en face confocal 
microscopy to follow endothelium repair in longitudinally opened 
and  attened mouse carotid arteries.
Results — We showed that E2 accelerates both migration and 
proliferation of endothelial cells and increased the recruitment of 
cells in an uninjured adjacent retrograde zone, leading to enlarged 
reendothelialized area (3).
Many studies suggest that circulating bone marrow (BM) derived 
cells are involved in arterial healing. Thus, we generated chimeric 
mice by grafting wild type mice with ERα -/- or ERα+/+ BM and 
vice versa. The bene cial effect of E2 was abolished when the ERα 
was absent either in donor or in receiver mice, demonstrating that 
both BM and non-BM ERα-expressing cells cooperate to mediate E2 
regenerative effects. Using a cell-speci c inactivation mouse model 
of ERα, by the loxP/Cre recombination system, we showed that 
endothelial ERα is absolutely required in the accelerative effect 
of E2 on reendothelialization. To precise which BM derived cells 
are involved in the E2 effect, the implication of ERα-expressing 
macrophages is now under investigation.
Conclusion — These results might help us to propose new strategy 
to optimize post-angioplasty and in-stent reendothelialization.
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